Rockets & Ripples into Close — Biotech Booms and Venue Vision

September 29, 2025

DENVER, Colo., Sep 29, 2025 (247marketnews.com)- Here are the names lighting up the tape right now and why they might stay lit into afterhours:

CleanSpark (NASDAQ:CLSK), known for its Bitcoin mining and energy infrastructure exposure, is under the spotlight after statements clarifying that a recent Nasdaq trading halt stemmed from a clerical warrant‑conversion error and not from issues in operations or financials.

The company’s earlier merger with GRIID Infrastructure also plays into volatility, the conversion of GRIID warrants into CleanSpark warrants was a core wrinkle.

With crypto sentiment stirring and regulatory headlines swirling, CLSK is a name to keep on your radar late in the session, especially when the crypto markets move.

VENU (NYSE:VENU) announced its 2025 Annual Meeting of Shareholders will be hosted October 28 at its Colorado Springs venue and framed the gathering as more than routine, calling it “a strategic spectacle for shareholders.”

The company is targeting 40 premium live music venues by 2030, with forecasts of $17.7 billion in economic impact across three flagship cities. CEO J.W. Roth emphasized the trajectory: “We are on pace to add more than $5 billion in completed project value in the next 36 to 48 months.”

With backing from names like Tixr, Aramark, and Troy Aikman, and with analyst upgrades entering the narrative, VENU is positioning a major narrative shift from venue operator to experiential real‑estate growth story. Expect sustained interest into the meeting and beyond.

Boqii (NYSE:BQ) has been quietly navigating major structural changes. The company terminated its ADR program, executed a 1-for-160 reverse stock split, and initiated a substitution listing so that its Class A ordinary shares now trade low‑float, as restructured, micro names, with small flows can have outsized impact.

On the fundamentals side, the recent H1 fiscal 2025 results showed declining revenues but improved operating efficiency and narrower losses.

Avalo Therapeutics (NASDAQ:AVTX)is making waves with its IL‑1β pipeline. The company recently announced a leadership appointment (Mike R. Lind to its board) and reaffirmed that topline data for its Phase 2 LOTUS trial (AVTX‑009 for hidradenitis suppurativa) is expected in 2026.

With ~$125 million in cash on hand, the company says its runway extends comfortably through 2027.

Merus (NASDAQ:MRUS) surged after Genmab struck a deal to acquire the oncology company in an all-cash transaction valued at about $8 billion, pegging Merus at $97 per share.

The premium deal underscores strong confidence in Merus’ lead asset petosemtamab (targeting head & neck cancer), and following today’s pop, MRUS is leading pre‑market futures for growth names.

In a strategic all-stock deal, Dogwood Therapeutics (NASDAQ:DWTX) is acquiring global rights to SP16, a promising treatment for chemotherapy-induced neuropathy (CIPN). Backed by funding from the National Cancer Institute, this move enhances Dogwood’s pain management portfolio alongside its existing Phase 2b candidate, Halneuron®.

CEO Greg Duncan emphasized non-dilutive growth: “The NCI’s funding obviates the need to use our existing capital in the near-term.”

Comscore (NASDAQ:SCOR) announced a pivotal recapitalization with its preferred stockholders, including Charter Communications and Liberty Broadband, aimed at eliminating over $18 million in annual dividend obligations, reducing board size, and enhancing corporate governance.

CEO Jon Carpenter said the changes will “strengthen Comscore’s foundation for long-term growth,” especially as the company seeks to lead in AI-driven media measurement.

The recap will require shareholder approval but could spark renewed interest in SCOR’s undervalued equity story. Shares were trading at a deep discount to the recap’s implied valuation.

Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.

For the full 24/7 Market News VENU report and in-depth insights, visit: Read 24/7 Market News VENU Report/

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated $2,500 per week by MicroCap Strategies for ongoing press and editorial coverage of VENU. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CLSK, VENU, BQ, AVTX, MRUS, DWTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.